Context Therapeutics (NASDAQ: CNTX) outlines T‑cell engager trials and cash runway

Rhea-AI Filing Summary

Context Therapeutics Inc. provided an updated corporate presentation outlining its strategy to build a leading T‑cell engager (TCE) pipeline for solid tumors and confirming an expected cash runway into mid‑2027. The company is advancing three CD3‑engaging bispecific antibodies: CTIM‑76 targeting Claudin 6, CT‑95 targeting mesothelin, and CT‑202 targeting Nectin‑4, all aimed at large relapse/refractory patient populations in ovarian, pancreatic, lung, bladder and other cancers.

CTIM‑76 is in an ongoing Phase 1a trial in CLDN6‑positive ovarian, endometrial and testicular cancers. As of October 2025, 12 heavily pretreated patients were enrolled, with linear pharmacokinetics, dose‑responsive T‑cell activity, no dose‑limiting toxicities, no cytokine release syndrome above Grade 1, and one confirmed partial response showing an 85% tumor reduction in platinum‑resistant ovarian cancer; interim Phase 1a data are anticipated in June 2026.

CT‑95 started a Phase 1a/1b dose‑escalation study in multiple mesothelin‑expressing tumors, with interim Phase 1a data expected in September 2026. CT‑202 remains preclinical, using pH‑dependent, avidity‑enhanced design to concentrate activity in the tumor microenvironment, with first patient dosing in a Phase 1 trial planned for the third quarter of 2026. Across the portfolio, preclinical models show selective tumor cell killing with efforts to reduce cytokine release and off‑tumor toxicity.

0001842952FALSE00018429522026-03-232026-03-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2026

Context Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-40654			86-3738787
(State of other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

2001 Market Street, Suite 3915, Unit #15

Philadelphia, Pennsylvania 19103

(Address of principal executive offices including zip code)

(267) 225-7416

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock

CNTX

The Nasdaq Stock Market

$0.001 par value per share

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On March 23, 2026, Context Therapeutics Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 8.01. Other Events.

Corporate Presentation

Slides 15 and 32 of Exhibit 99.1 to this Current Report on Form 8-K are hereby incorporated by reference into this Item 8.01.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Context Therapeutics Inc. Corporate Presentation — March 2026
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: Mach 23, 2026			Context Therapeutics Inc.
			By:			/s/ Martin A. Lehr
						Name: Martin A. Lehr
						Title: Chief Executive Officer

March 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “plan”, “predict”, “expect”, “estimate”, “anticipate”, “intend”, “goal”, “strategy”, “believe”, “could”, “would”, “potential”, “project”, “continue” and similar expressions and variations thereof. Forward-looking statements may include statements regarding the Company’s business strategy, cash flows, cash runway and funding status, potential growth opportunities, clinical development activities, the timing and results of preclinical research, clinical trials and potential regulatory approval and commercialization of product candidates. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements. Any forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in documents the Company has filed with the SEC. Any forward-looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. This presentation discusses product candidates that are under preclinical and clinical study, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. While the Company believes its internal research is reliable, such research has not been verified by any independent source. All the scientific, preclinical and clinical data presented within this presentation are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. Forward Looking Statement Executive Summary Context Therapeutics Inc. - March 20262

Building a Leading T cell Engager (TCE) Pipeline Executive Summary Strategy Developing potentially best-in-class TCE for solid tumors • Tumor antigens that are clinically validated by antibody drug conjugates (ADC) or chimeric antigen receptor T cell therapy (CAR-T) • Limited or weak competition addressing large market opportunities • High affinity CD3 to maximize solid tumor response Pipeline CTIM-76: Claudin 6 (CLDN6) x CD3 bispecific antibody • CLDN6 is overexpressed in ovarian, endometrial, lung, testicular, and other solid tumors • CTIM-76 was designed to bind selectively to CLDN6 over similar claudin family members, including CLDN3/4/9 CT-95: Mesothelin (MSLN) x CD3 bispecific antibody • MSLN is overexpressed in pancreatic, lung, colorectal, and other solid tumors • CT-95 was designed to bind selectively to membrane-bound MSLN to enhance drug exposure and activity CT-202: Nectin-4 x CD3 bispecific antibody • Nectin-4 is overexpressed in bladder, lung, breast, colorectal, and other solid tumors • CT-202 was designed to be conditionally active within the tumor microenvironment Capitalization Strong financial position with high quality investor base • Expected cash runway into mid-2027 Context Therapeutics Inc. - March 20263

Executive Summary Pipeline Overview Context Therapeutics Inc. - March 20264 PROGRAM TARGET ADDRESSABLE MARKET (U.S. ONLY) DISCOVERY DEVELOPMENT PHASE 1 PHASE 2 CTIM-76 Claudin 6 (CLDN6) > 50,000 patients CT-95 Mesothelin (MSLN) > 100,000 patients CT-202 Nectin-4 > 125,000 patients Ph 1a interim data expected June 2026 Ph 1a interim data expected Sept 2026 Ph 1 FPI expected Q3 2026 CTIM-76: CLDN6 x CD3 CT-95: MSLN x CD3 Product differentiation: highly selective for CLDN6 over CLDN3/4/9 Safety: potent CD3 induction without broad cytokine activation Potential Indications: ovarian, endometrial, lung α-CLDN6 Fab α-CD3 scFv α-MSLN Fab α-CD3 scFv CT-202: Nectin-4 x CD3 Product differentiation: avidity optimized to avoid mesothelin (MSLN) fragments Safety: sterically hindered CD3 to avoid T cell crosslinking Potential Indications: lung, pancreatic, ovarian, colorectal Product differentiation: conditionally activate in the tumor microenvironment Safety: sterically hindered CD3 to avoid T cell crosslinking Potential Indications: bladder, colorectal, breast, lung α-Nectin-4 Fab α-CD3 scFv

Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers Potential to expand into early treatment lines through synergistic drug combinations Executive Summary Context Therapeutics Inc. - March 20265 Synergistic Combination ApproachesOptimized Novel Monotherapies CTIM-76 CT-95 CT-202 Engineered for: Potential Opportunities for: • Best-in-class efficacy • Reduced CRS risk • Target selectivity • Pharmacokinetics • Complementary mechanisms to enhance activity • Improved safety due to non-overlapping toxicities • Synergistic immunologic effects TCE + ADC TCE + PD-1xVEGF + +

T Cell Engager Strategy Context Therapeut ics Inc . - March 20266

T Cell Engaging (TCE) Bispecific Antibodies T Cell Engager Strategy Context Therapeutics Inc. - March 20267 Mechanism of Action T-cell engagers (TCEs) are bispecific antibodies designed to redirect cytotoxic T lymphocytes toward malignant cells. These molecules simultaneously bind to a tumor-associated antigen on the cancer cell and to CD3, a component of the T-cell receptor complex. This dual engagement facilitates T-cell activation, immune synapse formation, and targeted cytolysis of tumor cells. TCE-mediated Cancer Cell Death TCE Bispecific Antibody T Cell Cancer Cell Target Antigen CD3 Cancer Cell Killing

10 FDA Approvals for TCE for Solid and Liquid Tumors Recently approved TCE have had strong initial commercial launches T Cell Engager Strategy Context Therapeutics Inc. - March 20268 2024202320222014 2025 Product Target 2025 Revenue1 Blincyto CD19 x CD3 $1,559 million Imdelltra DLL3 x CD3 $936 million Tecvayli BCMA x CD3 $670 million Talvey GPRC5D x CD3 $463 million Epkinly CD20 x CD3 $460 million Kimmtrak Gp100 x CD3 $400 million Columvi CD20 x CD3 $375 million Lunsumio CD20 x CD3 $148 million 1 Information from 2025 earnings filings and other public disclosures. Information provided is for illustrative purposes only and is not indicative of future performance.

TCE Success in Solid Tumors Asset Tarlatamab (AMG757) HPN328 QLS31905 IBI389 VIR-5500 JANX007 JNJ-78278343 Xaluritamig (AMG509) Ubamatamab (REGN4018) Target x Effector DLL3 x CD3 DLL3 x CD3 CLDN18.2 x CD3 CLDN18.2 x CD3 PSMA x CD3 PSMA x CD3 KLK2 x CD3 STEAP1 x CD3 MUC16 x CD3 Cancer Indication Small Cell Lung Small Cell Lung Pancreatic Pancreatic Prostate Prostate Prostate Prostate Ovarian Patients (n) 100 73 12 27 11 8 33 21 13 Efficacy ORR: 40% PFS: 4.9 mos. ORR: 55% DoR: 10.8 mos. ORR: 25% PFS: 3.9 mos. ORR: 38% PSA50: 100% ORR: 36% PFS: ~6 mos. PSA50: 100% ORR: 13% PFS: 7.9 mos. PSA50: 42% ORR: 8% PFS: 7.9 mos. PSA50: 50% ORR: 20% PFS: 7.8 mos. ORR: 31% Grade ≥ 3 CRS 1% 1% 3% 0% 2% 8% 0% 2% 0% Reference Ahn 2023 ESMO 2025 ASCO 2025 ASCO 2024 ASCO GU 2026 Dec 2025 data cutoff ASCO 2025 ESMO 2024 ESMO 2022 T Cell Engager Strategy Context Therapeutics Inc. - March 20269 Information provided in the table above as of March 1, 2026. Information provided is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies. TCE efficacy in cold tumors with a low rate of cytokine release syndrome (CRS)

CTIM-76 CLDN6 x CD3 bispecific antibody Context Therapeut ics Inc . - March 202610

CLDN6 Therapies Have the Potential to Reach a Large Patient Population >50,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CTIM-76 Program 11 Context Therapeutics Inc. - March 2026 Initial indications of interest based on: • CLDN6 prevalence • Patient population size • CLDN6 target validation Selected Cancer indications Incidence (US Only) R/R Incidence CLDN6 Positive CLDN6 Med/High Patient Population Based on R/R Incidence Ovarian 19,900 12,800 75%1 35%1 9,600 Endometrial 65,900 14,000 50%1 22%1 7,000 Testicular 9,910 400 100%3 >95%3 400 Non-Small Cell Lung 201,229 110,653 26%2 6%2 28,769 Colon 152,810 53,010 43%3 0%3 22,794 Breast 290,600 43,800 40%3 0%3 17,520 1 Context internal Phase 1 data; 2 Context internal biopsy prevalence screen data; 3 Mackensen, Nature Medicine, 2023. Incidences based on public estimates; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; CLDN6 target prevalence is based on IHC or RNAseq from published reports. Patient population derived from midpoint of CLDN6 positive population multiplied by R/R incident population.

CLDN6 is an Attractive Target for Immunotherapy • CLDN6 is an oncofetal protein. Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Expression increases with cancer disease stage • Tetraspan protein; does not readily internalize CTIM-76 Program Context Therapeutics Inc. - March 202612 CLDN6 is an Ideal TCE Target 1 Screnci, Cancer Res, 2022; 2 Tanaka, J Hepatol, 2018; 3 Cordat, Physiology, 2019; Li, FEBS Open Bio, 2020 CLDN6 selectivity is required to avoid off-target liabilities The CLDN6 antibody binding region is highly conserved with CLDN3 and CLDN4 – differing by only 3 amino acids1 CLDN3 and CLDN4 are enriched in the liver and antibody binding may result in liver enzyme elevations2,3 Avoiding CLDN3 and CLDN4 is a Critical Safety Determinant CLDN6 Protein Claudin Gene Family Extracellular Space Cytoplasm Antibody Binding Domain CLDN9 CLDN6 CLDN4 CLDN3 CLDN5 CLDN8 CLDN17 CLDN2 CLDN14 CLDN20 CLDN7 CLDN1 CLDN19 CLDN34 CLDN12 CLDN23 CLDN16 CLDN24 CLDN22 CLDN15 CLDN18 CLDN11 CLDN15 CLDN10

CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Optimized structure for CLDN6 selectivity, potency, and manufacturability • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functionally monovalent to avoid aberrant T cell activation • Silenced Fc domain to avoid off target immune cell activation Potentially wide therapeutic window • T cell dependent cellular cytotoxicity with no or minimal activation of circulating cytokines • Humanized CLDN6 and CD3 binding domains Ease of manufacturing • IgG1 backbone is highly stable and enables high yield CTIM-76 Program Context Therapeutics Inc. - March 202613 α-CLDN6 Fab α-CD3 scFv IgG1 backbone Silenced Fc Anticipate Interim Phase 1a Data in June 2026

CTIM-76 Program CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific Antibody Context Therapeutics Inc. - March 202614 Selectivity Potency In Vivo Efficacy • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently transfected in HEK-293F cells >10,000x • Potency assay provides a better assessment for a TCE bispecific than binding assays for off-target liabilities associated with CLDN3, CLDN4, or CLDN9 • CTIM-76 CLDN6 EC50 of 0.0004 nM (cytotoxicity) • CTIM-76 preferentially targets CLDN6, with minimal binding and cytotoxicity against CLDN9-expressing cells >500x 0 150 300 450 600 0 7 14 21 Tu m or V ol um e (m m 3) Day Vehicle 0.01mg/kg 0.1mg/kg 1.0mg/kg Tumor Regression • CTIM-76 effectively engaged systemically administered human PBMC cells to promote significant tumor regression and complete responses in OVCAR3 (~96,000 CLDN6 copies per cell) ovarian xenograft models in mice • CTIM-76 was well tolerated in OVCAR3 xenograft study • NSG-b2m knockout mice (n=14/arm) engrafted with human PBMCs and bearing advanced subcutaneous OVCAR3 tumor xenografts were treated twice per week

CTIM-76 Phase 1a Dose Escalation Trial Target population • Ovarian, endometrial and testicular cancer relapsed to standard of care • CLDN6+ positive via IHC (≥10% 1+ staining) Trial objectives • Assess safety and tolerability • Pharmacokinetic and pharmacodynamic data • Evaluate preliminary anti-tumor activity Dosing and Administration • Weekly IV infusion • Step dosing • Pretreat patients with 16 mg dexamethasone 1 hour prior to C1D1 and C1D8 doses CTIM-76 Program 15 22.5  70 µg (n=3) 70  140 µg (n=4) 22.5 µg (n=1) Anticipated path to the identification of optimal prime dose, full dose, and dosing schedule 140  280 µg (n=4) 140  560 µg (n=4) Cohorts at predicted sub-therapeutic doses 70  210 µg (n= 3-6) 70  280 µg (n=3-6) 1H 2026 Dose Optimization in ovarian patients 70  Low Dose (n=6-9) 70  High Dose (n=6-9) 2H 2026 Evaluate Q3W Dosing in ovarian patients Completed Trial status information provided as of March 20, 2026Context Therapeutics Inc. - March 2026

Summary of Preliminary Data from Ongoing Phase 1a Trial of CTIM-76 as of October 2025 Context anticipates providing updated interim Phase 1a data in June 2026 CTIM-76 Program Context Therapeutics Inc. - March 202616 12 patients enrolled: ovarian (7); testicular (3); endometrial (2) Median of 4 previous lines of therapy (range: 3-8) 5 patients are currently on treatment Patient Demographics Linear and dose proportional pharmacokinetics (PK) Potential to explore Q2W and/or Q3W dosing in future trials Dose responsive T cell migration and cytokine induction Dose Response Relationship Confirmed partial response (cPR) with an 85% reduction in tumor size is ongoing in Cohort 3 patient with platinum- resistant ovarian cancer (PROC) who progressed on prior FRα ADC Cohort 4 patients were not response evaluable at the time of data cutoff1 Efficacy No cytokine release syndrome (CRS) greater than Grade 1 No dose limiting toxicities (DLT) have been observed A maximum tolerated dose (MTD) has not been reached Safety Trial status information provided as of October 30, 2025. 1 Scans taken every 8 weeks

Clinical Programs Discontinued CTIM-76 XmAb541 ARC101 BGB-B455 AMG794 SAIL66 Company Context Xencor Third Arc BeOne Amgen Chugai Stage Ph 1 Ph 1 Ph 1 Ph 1 Ph 11 Ph 1 Bispecific Format 1 + 1 2 + 1 1 + 1 1 + 1 HLE Bite Dual Specific Fab CLDN3/4/9 Selectivity High1 Moderate2 High3 Not Disclosed4 High6 Moderate5 High Affinity CD3 ✘ ✘ ✘ ✘ Preclinical Tolerability Well tolerated Well tolerated Well tolerated Moderate tolerability Poor tolerability Poor tolerability CTIM-76 Program 17 Clinical trials.gov accessed on October 30, 2025 1 Rucker, SITC 2023 2 Faber, AACR 2021; Patent US11739144; 3 AACR 2025; 4 Patent US20240301061; 5 Kamikawa, SITC 2023; Patent WO2021006328; 6 Patent WO2022096700. Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Context Therapeutics Inc. - March 2026 CTIM-76 Competitive Landscape CTIM-76 incorporates a highly selective CLDN6 binder and high affinity CD3

CT-95 MSLN x CD3 bispecific antibody Context Therapeut ics Inc . - March 202618

MSLN Therapies Have the Potential to Reach a Large Patient Population >100,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-95 Program 19 Context Therapeutics Inc. - March 2026 Selected Cancer indications Incidence (US Only) R/R Incidence MSLN Positive MSLN Med/High Patient Population Based on R/R Incidence Non-Small Cell Lung 201,229 110,653 55% 36% 60,859 Pancreatic 66,440 51,750 80% 61% 41,400 Colon 152,810 53,010 41% 17% 21,734 Ovarian 19,900 12,800 90% 80% 11,520 Mesothelioma 3,000 2,500 70% 60% 1,750 Esophageal 22,370 16,130 41% 26% 6,613 Endometrial 65,900 14,000 45% 23% 6,300 Gastric 26,380 11,090 49% 23% 5,434 Incidences based on public estimates; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; MSLN target prevalence is based on Simon et al, Biomedicines, 2021. Patient population derived from MSLN positive population multiplied by R/R incident population. Initial indications of interest based on: • MSLN prevalence • Patient population size • MSLN target validation

MSLN Target Biology Shed mesothelin (sMSLN) in tumor microenvironment requires a creative solution to overcome CT-95 Program Context Therapeutics Inc. - March 202620 MSLN is bound to tumor cells via a GPI-anchor Like many GPI-anchored proteins, MSLN can be cut into smaller fragments1,2 The MSLN gene encodes a precursor that is cleaved into two products: a soluble N-terminal protein called megakaryocyte potentiating factor (MPF), and a membrane-bound fragment called full length mesothelin (FL-MSLN) sMSLN serves as a competitive sink, preventing antibodies from binding to the tumor, which can lead to suboptimal drug exposure and efficacy Overcoming Fragmented MSLN in the Tumor Microenvironment 1 Zhang, Transl Oncol, 2022; 2 Liu, Commun Biol, 2020; GPI = Glycosylphosphatidylinositol Precursor MSLN Protein FL-MSLNMPF Tumor Cell Enzymatic cleavage GPI sMSLN fragments Enzymatic cleavage

CT-95: MSLN x CD3 T cell Engaging (TCE) Bispecific Antibody Novel design to overcome mesothelin (MSLN) sink • Binds to membrane-proximal MSLN epitope • Affinity tuned MSLN binding • Cooperative binding results in high affinity binding of CT-95 to tumor Potentially wide therapeutic window • No crosslinking by shed MSLN, mitigating off-tumor T cell activation • Cooperative binding of MSLN on tumor surface crosslinks CD3, activating T cells Ease of manufacturing • IgG1 backbone is highly stable and enables high yield CT-95 Program Context Therapeutics Inc. - March 202621 α-MSLN Fab α-CD3 scFv IgG1 backbone Silenced Fc Anticipate Interim Phase 1a Data in September 2026

Cytotoxicity in the Presence of Soluble MSLN CT-95 Intended to Overcome MSLN Sink HPN-536 (Harpoon Therapeutics) binds to soluble MSLN (sMSLN) in a dose proportional manner, limiting therapeutic exposure CT-95 Program Context Therapeutics Inc. - March 202622 CT-95 +10nM sMSLN +30nM sMSLN HPN-536 +10nM sMSLN +30nM sMSLN HPN-536 clones are not derived from the original manufacturer and were produced for this research study based on the published sequence of their antibody variable chains; thus, the clones used in this study are biosimilars and may not be identical to the antibodies formulated for clinical development. OVCAR-3 Cytotoxicity OVCAR-3 Cytotoxicity

CT-95 Phase 1a/b Study An open-label, multi-center, dose escalation / expansion, safety, and PK study (NCT06756035) CT-95 Program 23 Context Therapeutics Inc. - March 2026 Trial status information provided as of March 20, 2026 0.3 µg/kg 0.18  0.6 µg/kg 0.27  0.9 µg/kg 0.36  1.2 µg/kg 0.48  1.6 µg/kg Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6 Active Dose Level 0.1 µg/kg MABEL Dose Completed (n=1) Completed (n=4) Phase 1a Dose EscalationBiomarker stratification • Ovarian, pancreatic, and mesothelioma do not require prospective screening • All other indications require prospective MSLN screening via IHC (≥10% 1+ staining) Trial objectives • Assess safety and tolerability at increasing dose levels • Pharmacokinetic and pharmacodynamic data • Evaluate preliminary anti-tumor activity Dosing and Administration • Weekly IV infusion • Single step dose • Pretreat patients with 10 mg dexamethasone 1 hour prior to C1D1 and C1D8 doses Enrolled (n=6) Completed (n=3)

CT-95 Competitive Landscape CT-95 is avidity enhanced, affinity tuned, and binds to membrane-bound MSLN CT-95 Program Context Therapeutics Inc. - March 202624 CT-95 AMG-305 HPN-536 JNJ-79032421 ZW171 Company Context Amgen4 Harpoon1 JNJ Zymeworks2,3 Format 2 + 2 1 + 1 + 2 CDH3 + MSLN dBiTE TriTAC 1+1 2 + 1 Avoids sMSLN ✘ ✘ ✘ Affinity Tuned ✘ ✘ ✘ ✘ High Affinity CD3 ✘ ✘ ✘ Program Status Phase 1 FPI Apr 2025 Phase 1 FPI Oct. 2023 Phase 1 Discontinued Phase 1 Discontinued Phase 1 Discontinued Clinical trials.gov accessed on October 30, 2025 1 Harpoon Therapeutics Corporate Presentation, 4 November 2021; 2 Piscitelli, PEGS Boston, 2023; 3 Zymeworks R&D Day, 2022; 4 WO2022096716A2. Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

CT-202 Nectin-4 x CD3 bispecific antibody Context Therapeut ics Inc . - March 202625

Nectin-4 Therapies Have the Potential to Reach a Large Patient Population >125,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-202 Program 26 Context Therapeutics Inc. - March 2026 Selected Cancer indications Incidence (US Only) R/R Incidence Nectin-4 Positive Nectin-4 Med/High Patient Population Based on R/R Incidence Colon 152,810 53,010 87%1 78%2 46,119 Bladder (urothelial) 83,190 20,000 83%3 60%3 16,600 Breast (TNBC) 62,054 15,500 78%3 58%5 12,090 Non-Small Cell Lung 201,229 110,653 64%3 58%6 70,818 Pancreatic 66,440 51,750 71%3 37%3 36,743 Head and Neck 54,000 12,000 59%3 18%3 7,080 Esophageal 22,370 16,130 55%3 24%3 8,872 Gastric 26,890 12,000 94%7 60%4 11,280 Initial indications of interest based on: • Nectin-4 prevalence • Patient population size • Target validation via antibody-drug conjugates (ADCs) Incidences based on public estimates; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; Patient population derived from Nectin-4 positive population multiplied by R/R incident population. 1 Kobecki, Int J Mol Sci, 2023; 2 Nikanjan, Can Let, 2025; 3 Challita, Can Res, 2016; 4 Zhang, Oncol Lett, 2018; 5 Zeindler, Front Med, 2019; 6 Takano, Mol Bio, 2009; 7 Muro, ESMO Open, 2025

CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody CT-202 Program Context Therapeutics Inc. - March 202627 α-Nectin-4 Fab α-CD3 scFv IgG1 backbone Silenced Fc Novel design incorporating logic gating to spare Nectin-4 in normal tissue • Because of its expression in healthy epidermal keratinocytes, sweat glands, and hair follicles, Nectin-4 targeted treatments are associated with dermatological side effects • CT-202 uses pH dependent binding to both Nectin-4 and CD3 to minimize binding to healthy tissues and maximize binding and T cell activation within the tumor microenvironment Avidity optimized to mitigate CRS risk • Bivalent Nectin-4 binding to reduce T cell crosslinking in the absence of target • Steric hindrance of CD3 binding by Fc domain prevents T cell crosslinking by single CT-202 molecules Ease of manufacturing • IgG1 backbone is highly stable and enables high yield Anticipate Phase 1 First Patient Dosed in Q3 2026

Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin CT-202 Program 28 Logic Gating Through pH Dependency + Increased Target Selectivity Through Avidity 1 Chang, PNAS, 2021 CD3 Potent T cell activationNo T cell activation High on-/off-rate when bound to Nectin-4 monomer Avidity-enhanced Nectin-4 binding T cell Tumor 30x gain of activity in acidic tumor microenvironment versus healthy cells1 Context Therapeutics Inc. - March 2026 No CT-202 Binding CT-202 Binding

CT-202 is Highly Active and Well Tolerated Across In Vivo Models CT-202 Program Context Therapeutics Inc. - March 202629 Complete Tumor Regressions CT-202 demonstrated similar efficacy in BT474 breast cancer xenograft compared to enfortumab TCE control antibodies in mice Reduced Cytokine Release CT-202 treatment resulted in significantly lower IL-6 induction compared to enfortumab TCE benchmark antibodies in NHP CT -2 02 En fo rt um ab T CE CT -2 02 En fo rt um ab T CE Control CT-202 1 mg/kg CT-202 0.5 mg/kg CT-202 0.25 mg/kg Control Enfortumab TCE 1 mg/kg Enfortumab TCE 0.5 mg/kg Enfortumab TCE 0.25 mg/kg CT-202 0.1 mg/kg CT-202 1 mg/kg CT-202 5 mg/kg Enfortumab TCE 0.1 mg/kg Enfortumab TCE 1 mg/kg Enfortumab TCE 5 mg/kg Padcev = enfortumab vedotin 30x Higher

CT-202 Competitive Landscape Competitor TCE programs lack conditional activation, avidity enhancement, and high potency immune activator Context Therapeutics Inc. - March 202630 Company Context Therapeutics Bicycle Therapeutics Rondo Therapeutics Asset CT-202 BT74801,2 RNDO-5643 Format 2 + 2 (pH dependent) 1 + 2 (Bicycle) 1 + 1 (Fixed light chain) Conditionally active ✘ ✘ Avidity enhanced ✘ ✘ High Affinity CD3 ✘ ✘ Program Status Preclinical (Ph 1 FPI expected Q3 2026) Phase 1 (completed) Preclinical (Ph 1 late 2025) 1 Bicycle Therapeutics R&D Day, Dec 2023; 2 Hurov, J Immunother Cancer, 2021; 3 PEGS Boston 2024. Information provided in the table above is for illustrative purposes only, is not exhaustive and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies. CT-202 Program

Corporate 31 Context Therapeut ics Inc . - March 2026

Anticipated Key Milestones in 2026-2027 • Multiple potential data inflection points over the next 18 months • Anticipated cash runway into mid-2027 Corporate PROGRAM target 1H 2026 2H 2026 1H 2027 2H 2027 CTIM-76 Claudin 6 (CLDN6) CT-95 Mesothelin (MSLN) CT-202 Nectin-4 Ph 1a Dose Escalation Ph 1a Q3W Dose Evaluation Ph 1b Dose Expansion Ph 1a Dose Escalation Ph 1b Dose Expansion Ph 1a Dose Escalation Context Therapeutics Inc. - March 202632

Corporate Experienced Leadership Team Experienced management team Clinical team has developed T cell therapies Our management team is supported by a Board with deep oncology experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Karen Chagin, MD Chief Medical Officer Context Therapeutics Inc. - March 202633 Jennifer Dashnau, PhD SVP Technical Operations Jennifer Minai Chief Financial Officer Chris Beck, MBA SVP Operations

Advancing T Cell Engagers for Solid Tumors © Context Therapeutics 2026

Glossary ADC Antibody drug conjugate AE Adverse event CAR-T Chimeric antigen receptor T cell therapy CD3 Cluster of differentiation 3 CLDN Claudin CRS Cytokine release syndrome DLT Dose limiting toxicity Fab Fragment antigen-binding region FIH First-in-human FPI First Patient In (dosed) FRα Folate receptor alpha GPI Glycosylphosphatidylinositol IHC Immunohistochemistry IND Investigational new drug IV Intravenous Mabel Minimum anticipated biologic effect level MoA Mechanism of action MSLN Mesothelin MTD Maximum tolerated dose Appendix Context Therapeutics Inc. - March 202635 N.D. Not disclosed ORR Overall response rate PFS Progression free survival PK Pharmacokinetic PR Partial Response PROC Platinum resistant ovarian cancer Q2W Every two weeks Q3W Every three weeks RP2D Recommended Phase 2 dose TCE T cell engager scFv Single chain variable fragment

FAQ

What did Context Therapeutics (CNTX) disclose in its latest corporate presentation?

Context Therapeutics updated its corporate presentation, highlighting a T‑cell engager pipeline targeting solid tumors, key clinical timelines through 2027, and an expected cash runway into mid‑2027, along with early Phase 1a data for lead asset CTIM‑76 in CLDN6‑positive cancers.

What is Context Therapeutics’ lead program CTIM-76 and what data have been reported?

CTIM‑76 is a Claudin 6 x CD3 bispecific antibody for CLDN6‑positive solid tumors. Early Phase 1a data in 12 heavily pretreated patients showed dose‑proportional pharmacokinetics, no dose‑limiting toxicities, only Grade 1 cytokine release, and one confirmed partial response with an 85% tumor reduction in platinum‑resistant ovarian cancer.

What are the key upcoming milestones for Context Therapeutics (CNTX) in 2026-2027?

Planned milestones include CTIM‑76 interim Phase 1a data in June 2026, CT‑95 interim Phase 1a data in September 2026, evaluation of alternative CTIM‑76 dosing schedules in 2026, CT‑95 dose expansion, and first patient dosing for CT‑202, a Nectin‑4 x CD3 bispecific, in a Phase 1 trial in Q3 2026.

How strong is Context Therapeutics’ financial position according to the presentation?

The presentation states Context Therapeutics has a strong financial position with an expected cash runway into mid‑2027. This suggests current cash resources are planned to support advancement of the CTIM‑76, CT‑95 and CT‑202 programs through multiple clinical milestones over the next several years.

What cancer types are targeted by Context Therapeutics’ T-cell engager pipeline?

CTIM‑76 targets CLDN6‑positive ovarian, endometrial, lung, testicular and other tumors. CT‑95 addresses mesothelin‑positive cancers such as pancreatic, lung, colorectal, ovarian and mesothelioma. CT‑202 targets Nectin‑4 in bladder, lung, breast, colorectal, pancreatic and other solid tumors with large relapse/refractory populations.

How is Context Therapeutics aiming to reduce cytokine release syndrome risk in its TCE programs?

The programs use engineering features such as functionally monovalent CD3 binding, silenced Fc domains, avidity‑enhanced target binding and, for CT‑202, pH‑dependent binding. These design choices aim to concentrate T‑cell activation within tumors and minimize systemic cytokine release and off‑tumor toxicities.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 39.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 23.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 13.8 KB